What is Datavant?
Datavant is a privately owned computer software company founded in 2017 and headquartered in San Francisco, California. The company specializes in linking and sharing healthcare data across multiple platforms, aiming to enhance medical research and improve patient care. Datavant also provides assistance with data safety and sharing operations, positioning itself as a critical infrastructure provider in the health tech sector. Its focus on secure data exchange is paramount in an era demanding both innovation and stringent privacy controls.
How much funding has Datavant raised?
Datavant has raised a total of $121M across 3 funding rounds:
Series A
$40.5M
Other Financing Round
$40.5M
Series B
$40M
Series A (2018): $40.5M with participation from Roivant Sciences
Other Financing Round (2018): $40.5M led by Roivant Sciences
Series B (2020): $40M supported by Johnson & Johnson Innovation – JJDC, Inc., Cigna Ventures, Flex Capital, Roivant Sciences Ltd., and Transformation Capital Group Ltd
Key Investors in Datavant
Johnson & Johnson Innovation – JJDC, Inc.
Johnson & Johnson Innovation – JJDC, Inc. is the venture capital arm of Johnson & Johnson, focusing on investing in early-stage companies that align with Johnson & Johnson's strategic interests in healthcare innovation.
Cigna Ventures
Cigna Ventures is the corporate venture capital unit of Cigna, investing in companies that enhance health services, improve health outcomes, and drive innovation in the healthcare ecosystem.
Flex Capital
Flex Capital is an investment firm that likely focuses on providing strategic capital to companies, potentially within the technology or healthcare sectors, to support their growth and market penetration.
What's next for Datavant?
The substantial enterprise-level funding Datavant has attracted indicates a strong market validation and positions the company for significant scaling and expansion. This capital infusion is expected to fuel further development of its data-linking technologies, broaden its market reach, and potentially support strategic acquisitions. The company's trajectory suggests a move towards solidifying its leadership in the health data interoperability space, enabling more robust and efficient medical research and patient outcome improvements.
See full Datavant company page
